Epidermal Growth Factor Receptor Exon 20 Mutation Increased in Post-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples

作者: Wang Y, Bao WL, Shi H, Jiang CM, Zhang YJ
成果类型: 期刊论文
数据来源: ESI SCIE
发表日期: 2013
年卷期页: 2013,6,(4),504-510
期刊名: 《TRANSLATIONAL ONCOLOGY》 影响因子和分区 年份    影响因子    区号
2016    3.025        3区 2015    3.077        3区 2014    2.884        3区 2013    2.943        3区
缩写刊名: TRANSL ONCOL
英文关键词: TYROSINE KINASE INHIBITOR; PREVIOUSLY TREATED PATIENTS; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; T790M MUTATION; EGFR MUTATIONS; GENE-MUTATIONS; SOLID TUMORS; OPEN-LABEL; GEFITINIB
英文摘要: PURPOSE: Patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)-mutations have excellent response to EGFR tyrosine kinase inhibitors (TKIs), and exon 20 mutation accounts for most of TKI drug resistance. Nested polymerase chain reaction (PCR) was used to detect EGFR exon 20 mutations of patients with NSCLC after chemotherapy. The same is being analyzed with patients' characteristics. METHODS: Peripheral blood samples were collected from 273 patients with NSCLC, including 143 with adenocarcinoma (ADC) and 130 with squamous cell carcinoma (SCC), after chemotherapy. DNA was extracted from whole blood for nested PCR amplification and purification. Sequencing was carried out in an automated 3730 sequencer, followed by analysis of EGFR exon 20 mutations from nested PCR products. RESULTS: The mutations of EGFR exon 20 were mainly point mutations in rs1050171 (c.2361A>G) and rs56183713 (c.2457G>A). The point mutation was 28.21%, 28.46%, and 27.97% in patients with NSCLC, ADC and SCC, respectively. Men had an equivalent mutation (27.18%) to women (30.77%). The mutation in smokers and nonsmokers was 27.68% and 29.17%, respectively. In unselected patients, there was no correlation between EGFR exon 20 mutations and patients' characteristics of age, gender, smoking history, histologic type, or tumor-node-metastasis (TNM) staging system. In subgroup analyses, the EGFR mutation of patients with SCC was correlated with TNM stage [P = .013; odds ratio = 1.758; 95% confidence interval (CI) = 1.125-2.747]. CONCLUSIONS: The data indicate that the chemotherapy may induce EGFR-TKI-resistant mutation in NSCLC cells and EGFR-TKI should be used in the early stage of NSCLC but not after chemotherapy.
语言: English
出版类型: Article
主题: Oncology
EISSN: 1936-5233
作者邮箱: zhangyongjun770323@163.com  
作者地址: [Wang, Ying] Zhejiang Chinese Med Univ, Dept Basic Med Sci, Hangzhou, Zhejiang, Peoples R China
[Bao, Wenlong; Shi, Hua; Jiang, Chuming; Zhang, Yongjun] Zhejiang Canc Hosp, Dept Integrat Tradit Chinese & Western Med, Hangzhou 310022, Zhejiang, Peoples R China
[Zhang, Yongjun] Zhejiang Canc Hosp, Zhejiang Key Lab Diag & Treatment Technol Thorac, Hangzhou 310022, Zhejiang, Peoples R China
基金支持数量: Zhejiang Provincial Traditional Chinese Medicine Foundation for Outstanding Young Talent [2012ZQ005]
基金: Funded by Zhejiang Provincial Traditional Chinese Medicine Foundation for Outstanding Young Talent (No. 2012ZQ005). Conflict of interest statement: None declared.
出版社: NEOPLASIA PRESS
出版地址: 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA
参考文献: [0]Bai H, 2009, J CLIN ONCOL, V27, P2653, DOI 10.1200/JCO.2008.17.3930
[1] Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100
[2] Bezjak A, 2006, J CLIN ONCOL, V24, P3831, DOI 10.1200/JCO.2006.05.8073
[3] Chang A, 2006, J THORAC ONCOL, V1, P847, DOI 10.1097/01243894-200610000-00014
[4] Chmielecki J, 2009, AM ASS CANC RES ANN
[5] Ettinger DS, 2012, J NATL COMPR CANC NE, V10, P292
[6] Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038
[7] Giaccone G, 2004, ANN ONCOL, V15, P831, DOI 10.1093/annonc/mdh188
[8] Han Rubing, 2011, Zhongguo Fei Ai Za Zhi, V14, P127, DOI 10.3779/j.issn.1009-3419.2011.02.04
[9] Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388
[10] Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038
[11] Hirsch FR, 2009, LANCET ONCOL, V10, P432, DOI 10.1016/S1470-2045(09)70110-X
[12] Howlader N, SEER CANC STAT REV 1
[13] Huang SF, 2004, CLIN CANCER RES, V10, P8195, DOI 10.1158/1078-0432.CCR-04-1245
[14] Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951
[15] Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714
[16] Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818
[17] Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149
[18] Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
[19] Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
[20] Marchetti A, 2005, J CLIN ONCOL, V23, P857, DOI 10.1200/JCO.2005.08.043
[21] Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504
[22] Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158
[23] Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X
[24] Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
[25] National Cancer Center, 2013, CHIN CANC REG ANN RE
[26] Onitsuka T, 2010, LUNG CANCER, V68, P198, DOI 10.1016/j.lungcan.2009.05.022
[27] Oxnard GR, 2011, CLIN CANCER RES, V17, P1616, DOI 10.1158/1078-0432.CCR-10-2692
[28] Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
[29] Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947
[30] Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
[31] Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658
[32] Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X
[33] Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158
[34] Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494
[35] Shigematsu H, 2005, J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
[36] Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
[37] Su KY, 2012, J CLIN ONCOL, V30, P433, DOI 10.1200/JCO.2011.38.3224
[38] Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8
[39] Tokumo M, 2005, CLIN CANCER RES, V11, P1167
[40] Wu YL, 2007, J THORAC ONCOL, V2, P430, DOI 10.1097/01.JTO.0000268677.87496.4c
[41] Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X
全文链接:
相关文献
作者其它文献
My JSP 'reqreturndiv.jsp' starting page